This protocol applies to premenopausal, reproductive-age patients with cervical stricture or stenosis — specifically those who are not postmenopausal and have not received gonadotropin-releasing hormone analogs.
In premenopausal women, estrogen levels are preserved — a distinction that directly affects how cervical ripening agents perform. In postmenopausal women and those in a hypoestrogenic state (including those treated with gonadotropin-releasing hormone analogs), certain pharmacological approaches show decreased effectiveness, as prostaglandins require estrogen to exert their cervical ripening effects.
This protocol is designed for the estrogen-replete, premenopausal context, where the full range of ripening options is applicable.
The primary objective is restoration of patency of the cervical canal, enabling adequate cervical dilation for planned hysteroscopy.
Management involves preprocedural cervical ripening before hysteroscopy, drawing on both pharmacological and mechanical options. The choice between approaches — and the specific agents, timing, and conditions under which each is preferred — is detailed in the full protocol.
DOI: 10.1007/s00404-023-07126-1
In postmenopausal women and those treated with gonadotropin-releasing hormone analogs, misoprostol has a decreased effect since prostaglandins require estrogen to generate their cervical ripening effects, and postmenopausal patients are in a hypoestrogenic state.
It is a prostaglandin E1 analogue, that ease cervical dilation through its estrogen-mediated effects on the cervix.
The insertion of laminaria stems before the procedure is intended to simplify the cervical dilation.
The main objective of both medical and surgical treatments for cervical stenosis is to restore the patency of the cervical canal.
View source ↗